<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03862365</url>
  </required_header>
  <id_info>
    <org_study_id>2017/1593</org_study_id>
    <nct_id>NCT03862365</nct_id>
  </id_info>
  <brief_title>Exploring the Genetics of Neuropathic Pain</brief_title>
  <acronym>GeNeup</acronym>
  <official_title>Exploring the Genetics of Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Pain Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo Metropolitan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the present study the investigators will search for new genetic variants relevant for the
      development of neuropathic pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neuropathic pain is defined as &quot;pain caused by a lesion or disease of the somatosensory
      nervous system&quot;. Neuropathic pain is a huge health problem worldwide, with an estimated
      prevalence of 7-8 % in the general population. In the present study the investigators will
      search for new genetic variants relevant for the development of this type of pain.

      Peripheral nerve lesions only progress to neuropathic pain in some patients, yet is not
      completely understood why or how. Genetic studies of patients with rare neuropathic disorders
      have been important for elucidating novel molecular mechanisms of neuropathic pain, and new
      drugs for neuropathic pain are now being developed based on these findings. By using genetic
      association studies, one may identify new genetic variants which may help to identify key
      molecular mechanisms for a larger group of patients with neuropathic pain.

      This project will use existing population-based cohorts, as well as establish a specific
      registry and biobank for patients with neuropathy in order to address these specific needs.
      This will allow the investigators to identify a large number of individuals with probable
      neuropathic pain and individuals with pain-free peripheral neuropathy (disease controls).
      International collaboration will contribute to study a large group of patients, which will be
      important in order to reach the project's goals. The results from the project are expected to
      increase current knowledge on the mechanisms of neuropathic pain, opening up new
      opportunities for innovative and improved treatments.

      Dissemination of results will be organized in close collaboration with patient
      representatives, and will be done regularly throughout the course of the project. The will
      focus both on internal dissemination to the participating hospitals, and external
      dissemination through participation in conferences, submissions to scientific journals and by
      publishing patient-friendly information booklets and proactively informing media outlets and
      patient organizations.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2027</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Genetic variants associated with neuropathic pain.</measure>
    <time_frame>Baseline</time_frame>
    <description>Relevant genotypes will be found using genome-wide association study (GWAS) methodology, ie. with no assumptions regarding which genetic variants that may be relevant (no hypotheses regarding specific variants). This is going to be conducted by using array genotyping (SNPs) in order to identify genetic variants that might be associated with neuropathic pain. Genetic variants will be defined and named according to standard practice, without any room for local or study specific adaptations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phenotype; neuropathic pain yes/no</measure>
    <time_frame>Baseline</time_frame>
    <description>Patients will be divided in two groups; neuropathy With pain (= neuropathic pain) and neuropathy without pain. For definition of neuropathic pain, the Neupsig guidelines (Finnerup et al, Pain 2016) will be used.It is estimated that about 600 patients will be included yearly for this purpose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phenotype; subgroup analysis of patients with neuropathic pain based on grading of pain</measure>
    <time_frame>Baseline</time_frame>
    <description>Patients with neuropathic pain will be further subdivided in groups based on pain reports. Pain will be graded using validated questionnaires. The &quot;Brief Pain Inventory-BPI&quot; (Cleeland et al, 1994) questionnaire will be used as primary resource for pain grading, on a scale from 0 to 10 (0: no pain, 1-3: mild pain, 4-10: strong pain).</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Neuropathic Pain</condition>
  <condition>Genetic Predisposition</condition>
  <condition>Polyneuropathies</condition>
  <arm_group>
    <arm_group_label>Polyneuropathy with pain</arm_group_label>
    <description>Clinical and diagnostic test evaluation for the establishment of polyneuropathy with pain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polyneuropathy without pain</arm_group_label>
    <description>Clinical and diagnostic test evaluation for the establishment of polyneuropathy without pain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic polyneuropathy with pain</arm_group_label>
    <description>Clinical and diagnostic test evaluation for the establishment of diabetic polyneuropathy with pain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic polyneuropathy without pain</arm_group_label>
    <description>Clinical and diagnostic test evaluation for the establishment of diabetic polyneuropathy without pain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carpal tunnel syndrome with pain</arm_group_label>
    <description>Clinical and diagnostic test evaluation for the establishment of carpal tunnel syndrome with pain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carpal tunnel syndrome without pain</arm_group_label>
    <description>Clinical and diagnostic test evaluation for the establishment of carpal tunnel syndrome without pain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Nerve conduction Studies</intervention_name>
    <description>Patients will be genotyped for comparison of patients With and without pain, With different clinical subgroups as mentioned.</description>
    <arm_group_label>Carpal tunnel syndrome with pain</arm_group_label>
    <arm_group_label>Carpal tunnel syndrome without pain</arm_group_label>
    <arm_group_label>Diabetic polyneuropathy with pain</arm_group_label>
    <arm_group_label>Diabetic polyneuropathy without pain</arm_group_label>
    <arm_group_label>Polyneuropathy with pain</arm_group_label>
    <arm_group_label>Polyneuropathy without pain</arm_group_label>
    <other_name>Genetical analysis</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood + blood for Expression analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients that are referred for suspected distal symmetric polyneuropathy and meet the
        inclusion criteria, will be included in the project. Furthermore, there will be collected
        blood tests from patients with definite and probable polyneuropathy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient is between 18 and 70 years old.

          2. The patient has consented.

          3. The patient is referred for evaluation of possible distal symmetric polyneuropathy
             (DSPN).

          4. The patient has filled out the questionnaires.

        Exclusion Criteria:

          1. The patient is too sick to participate (eg. bedridden, fever).

          2. The patient is unable to consent (eg. dementia, speech problems, psychiatric
             disorder).

          3. Inflammatory acute polyneuropathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Anker Zwart, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Benett, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ina Hjelland, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margreth Grotle, Pr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo Metropolitan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie Bu Kvaløy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helse Stavanger HF</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trond Sand, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Olavs Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sissel Løseth, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Troels Jensen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish pain research senter</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristian B. Nilsen, M.D</last_name>
    <phone>+4791372241</phone>
    <email>uxnikq@ous-hf.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ina Hjelland, M.D.</last_name>
      <phone>+4755975000</phone>
      <email>ina.hjelland@helse-bergen.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0450</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristian B. Nilsen, M.D.</last_name>
      <phone>+4791372241</phone>
      <email>uxnikq@ous-hf.no</email>
    </contact>
    <contact_backup>
      <last_name>Ioannis Kitsos, M.D.</last_name>
      <phone>+4722117769</phone>
      <email>ioakit@ous-hf.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Helse Stavanger HF</name>
      <address>
        <city>Stavanger</city>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Bu Kvaløy, M.D.</last_name>
      <phone>+4751518430</phone>
      <email>marie.bu.kvaloy@sus.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Norway</name>
      <address>
        <city>Tromsø</city>
        <zip>9019</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sissel Løseth, M.D.</last_name>
      <phone>+4777627102</phone>
      <email>sissel.loseth@unn.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7030</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trond Sand, M.D.</last_name>
      <phone>+4772576006</phone>
      <email>trond.sand@ntnu.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 11, 2018</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Kristian Bernhard Nilsen</investigator_full_name>
    <investigator_title>Senior Consultant, phd</investigator_title>
  </responsible_party>
  <keyword>reliability</keyword>
  <keyword>validity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Genetic Predisposition to Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

